Table 1

Relative hepatic mEH and major GST mRNA levels in response to ACF

	Relative mRNA Levels
	Untreated		TH		ADS		OZ		CL
	−ACF	+ACF	−ACF	+ACF	−ACF	+ACF	−ACF	+ACF	−ACF	+ACF
mEH	1	0.4 ± 0.2	17.9 ± 4.9	9.1 ± 2.5^1-a	9.1 ± 3.8	0.3 ± 0.2^1-a	14.4 ± 3.5	1.1 ± 0.2^1-a	7.0 ± 1.6	2.8 ± 0.7^1-a
rGSTA2	1	0.8 ± 0.5	14.3 ± 6.8	10.2 ± 3.2	12.0 ± 5.6	1.0 ± 0.6^1-a	18.4 ± 7.1	2.3 ± 0.2^1-a	13.7 ± 6.0	5.6 ± 2.0^1-a
rGSTA3	1	0.7 ± 0.4	2.3 ± 0.3	1.3 ± 0.1^1-a	2.4 ± 0.5	1.6 ± 0.2^1-a	2.7 ± 0.4	1.0 ± 0.1^1-a	1.4 ± 0.1	1.3 ± 0.2
rGSTM1	1	0.5 ± 0.2^1-a	2.6 ± 0.1	1.7 ± 0.1^1-a	1.8 ± 0.5	0.4 ± 0.2^1-a	1.9 ± 0.1	0.8 ± 0.1^1-a	1.7 ± 0.1	0.8 ± 0.1^1-a
rGSTM2	1	0.6 ± 0.2^1-a	1.9 ± 0.1	1.6 ± 0.1	1.3 ± 0.4	0.4 ± 0.2^1-a	1.8 ± 0.1	0.5 ± 0.1^1-a	2.2 ± 0.1	0.5 ± 0.1^1-a

Northern blot analysis was performed with total RNA fractions isolated from untreated animals or rats at 24 hr after treatment with a single dose of TH (100 mg/kg, ip), ADS (100 mg/kg, po), OZ (100 mg/kg, po), or CL (100 mg/kg, po), with or without a concomitant injection of ACF (20 mg/kg, im). Changes in the mRNA levels, relative to GAPDH, were assessed by scanning densitometry. Each value represents the mean ± SD from three separate animal experiments. Data were analyzed by one-way analysis of variance followed by the Newmann-Keuls test for comparison of multiple group means.

↵1-a p < 0.05, in comparison with the respective −ACF control.